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Linear ubiquitination is involved in the pathogenesis
of optineurin-associated amyotrophic lateral
sclerosis
Seshiru Nakazawa1,2,*, Daisuke Oikawa1,3,*, Ryohei Ishii4,*, Takashi Ayaki5,6, Hirotaka Takahashi7,
Hiroyuki Takeda7, Ryuichiro Ishitani4, Kiyoko Kamei1, Izumi Takeyoshi2, Hideshi Kawakami8, Kazuhiro Iwai9,
Izuho Hatada10, Tatsuya Sawasaki7, Hidefumi Ito5, Osamu Nureki4 & Fuminori Tokunaga1,3
Optineurin (OPTN) mutations cause neurodegenerative diseases, including amyotrophic
lateral sclerosis (ALS) and glaucoma. Although the ALS-associated E478G mutation in the
UBAN domain of OPTN reportedly abolishes its NF-kB suppressive activity, the precise
molecular basis in ALS pathogenesis still remains unclear. Here we report that the
OPTN-UBAN domain is crucial for NF-kB suppression. Our crystal structure analysis reveals
that OPTN-UBAN binds linear ubiquitin with homology to NEMO. TNF-a-mediated NF-kB
activation is enhanced in OPTN-knockout cells, through increased ubiquitination and
association of TNF receptor (TNFR) complex I components. Furthermore, OPTN binds
caspase 8, and OPTN deﬁciency accelerates TNF-a-induced apoptosis by enhancing complex
II formation. Immunohistochemical analyses of motor neurons from OPTN-associated ALS
patients reveal that linear ubiquitin and activated NF-kB are partially co-localized with
cytoplasmic inclusions, and that activation of caspases is elevated. Taken together, OPTN
regulates both NF-kB activation and apoptosis via linear ubiquitin binding, and the loss of this
ability may lead to ALS.
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T
he nuclear factor-kB (NF-kB) pathway is a central signal
transduction pathway regulating inﬂammation, adaptive
and innate immune responses, and cell death, mostly
through transcriptional targets. Therefore, impaired NF-kB
activity is implicated in diverse disorders, including inﬂamma-
tory, autoimmune and neurodegenerative diseases, metabolic
syndrome and cancers1,2. Posttranslational modiﬁcations,
such as phosphorylation and ubiquitination, regulate the NF-kB
activation pathways3. In ubiquitination, a Lys63 (K63)-linked
polyubiquitin chain, generated by tumour-necrosis factor (TNF)
receptor-associated factor proteins, plays a crucial role as a
scaffold to recruit the TAK1 (transforming growth factor-b-
activated kinase 1)–TAK1-binding protein complex, which then
phosphorylates inhibitor of NF-kB (IkB) kinase b (IKKb)4.
IKK, composed of two kinase subunits (IKKa and IKKb) and a
non-catalytic regulatory subunit, NEMO, phosphorylates IkB.
Phosphorylated IkB is degraded through the ubiquitin–
proteasome system, allowing the intranuclear translocation of
NF-kB and subsequent induction of transcriptional targets.
In parallel to NF-kB activation mediated by the K63-linked
ubiquitin chain, we previously showed that the linear ubiquitin
chain assembly complex (LUBAC) composed of HOIL-1L
(also known as RBCK1), HOIP (RNF31) and SHARPIN,
speciﬁcally generates the amino-terminal Met1 (M1)-linked
linear polyubiquitin chain5. NF-kB activation is induced
by linear ubiquitination of NEMO and RIP1 by LUBAC, on
stimulation by proinﬂammatory cytokines6,7. The linear ubiquitin
chain then functions as a scaffold to recruit the IKK complex via
the linear ubiquitin-speciﬁc binding site of NEMO, named UBAN
domain6,8,9. IKK complexes recruited to linear ubiquitin chains
are then activated by trans-phosphorylation, which ﬁnally
initiates canonical NF-kB signalling by subsequent phos-
phorylation of IkB10. Thus, proteins with linear ubiquitin-
speciﬁc binding domains, such as the UBAN domain, play
pivotal roles in the recognition and regulation of linear ubiquitin-
mediated signalling.
Optineurin (OPTN, also called FIP2 and NRP) and
A20-binding IkB proteins contain a UBAN domain11. Among
them, OPTN exhibits the highest sequence homology to
NEMO12. Unlike NEMO, OPTN does not interact with IKKa
and IKKb13; however, OPTN suppresses NF-kB activity by
competing with NEMO function14. Furthermore, OPTN binds
IKK subfamily protein kinases, such as TANK-binding kinase 1
(TBK1) and IKKe (also called IKKi), thus contributing to
virus-triggered interferon IFN production pathways15,16 and
Salmonella-induced autophagy17. Recently, OPTN, as well as
NDP52, was identiﬁed as major factors in mitophagy and OPTN
phosphorylation by TBK1 regulates these process18–20. OPTN
also reportedly associates with Rab8 and myosin VI, to regulate
vesicular trafﬁcking and Golgi morphology21,22. Importantly,
mutations in OPTN are associated with neurodegenerative
disorders. First, mutations in OPTN, such as E50K, were
identiﬁed as inducing primary open-angle glaucoma (POAG)23.
Subsequently, other mutations in OPTN, such as Q398X and
E478G, were detected in patients with familial amyotrophic
lateral sclerosis (ALS)24. ALS is a progressive neurodegenerative
disease affecting motor neurons and, although most cases are
sporadic, about 10% are familial. Currently, mutations in B20
genes, such as superoxide dismutase 1 (SOD1), TAR DNA-binding
protein 43 (TDP-43), FUS, ubiquilin 2, p62 (SQSTM1), p97 (VCP),
TBK1 and OPTN, were identiﬁed as responsible for familial ALS.
Mutations in OPTN are minor, but evident for familial ALS25,26.
Moreover, variants of OPTN are also linked with Paget’s disease
of the bone27 and frontotemporal lobe dementia28. However, the
roles of OPTN in the pathophysiology of neurodegenerative
disorders have yet to be determined.
Here we show that among the OPTN mutations reported in
POAG and ALS, most of the ALS-associated mutants fail to
suppress NF-kB activation. OPTN mutants without inhibitory
effects have either a mutation or deletion of the UBAN domain.
The crystal structure of OPTN-UBAN in complex with linear
tetraubiquitin reveals that the residues involved in linear
ubiquitin binding correspond to the residues crucial for
suppression of NF-kB activation. Furthermore, we analyse
the NF-kB activation by constructing CRISPR/Cas9-directed
OPTN-knockout (KO) cells. We ﬁnd that OPTN also functions in
the TNF-a-induced extrinsic apoptosis pathway. By examining
OPTN-associated ALS patients’ samples, we detect linear
ubiquitin and activated NF-kB in cytoplasmic inclusions, with
association of enhanced apoptosis. Taken together, our ﬁndings
indicate that OPTN is involved in critical signalling pathways and
the disruption of these cellular functions of OPTN is involved in
ALS pathogenesis.
Results
Dysregulation of NF-jB by ALS-associated OPTN mutations.
OPTN consists of multiple domains, such as leucine zipper,
LC3-interacting region (LIR), two coiled-coil (CC1 and CC2),
UBAN and Npl4-type zinc ﬁnger (Fig. 1a)12. In vitro experiments
have linked OPTN to various signalling pathways. However,
the domains and pathways involved in the pathogenesis of
OPTN-associated diseases still remain unclear. At present,
missense mutations of OPTN, such as H26D, E50K, M98K,
E322K, H486R and R545Q, were linked to POAG, and R96L,
Q165X, Q398X, Q454E and E478G (X denotes a stop codon)
mutations were identiﬁed from familial ALS patients12,29
(Fig. 1a). Furthermore, we employed the non-pathogenic
D474N mutant, with a mutation in the UBAN domain, as its
abilities to induce defects in endocytic trafﬁcking, NF-kB and IFN
signalling, and mitophagy have been well characterized14,19,30.
To identify the residues and domains directly involved in the
pathogenesis of ALS and POAG, we performed a comprehensive
analysis by using these 12 OPTN mutants. As OPTN shows high
similarity with NEMO, a crucial factor in the NF-kB activation
pathway, we examined the effect of these OPTN mutants on
LUBAC- and TNF-a-mediated NF-kB activation by luciferase
reporter assays (Fig. 1b). Expression of OPTN wild type (WT) or
POAG-associated OPTN mutants strongly suppressed LUBAC-
and TNF-a-mediated NF-kB activation. However, the inhibitory
effect was lost in the Q165X, Q398X, D474N and E478G mutants,
and the Q454E and H486R mutants also showed partially reduced
inhibitory effects. Although it was previously reported that
missense mutations in the UBAN domain of OPTN, such as
D474N and E478G, abolished the suppressive effect of OPTN on
TNF-a-mediated NF-kB activation14,24, we conﬁrmed here that
the UBAN domain is also critical for LUBAC-mediated NF-kB
regulation. Interestingly, most of the OPTN mutants that lost the
inhibitory effect were those with ALS-associated mutations,
suggesting that impaired suppression of NF-kB activation due
to mutations in OPTN may play a key role in the pathogenesis of
OPTN-associated ALS.
Next, to identify the inhibitory target of OPTN, we examined
the effects of OPTN-WT and OPTN-E478G mutant on NF-kB
activation induced by overexpression of NF-kB activators
(Supplementary Fig. 1). OPTN reportedly suppressed NF-kB
activation induced by RIP1, but not that by a constitutively active
mutant of IKKb (IKKb-EE)14. In addition, OPTN lacked
inhibitory effects on the non-canonical NF-kB activation
pathway induced by NF-kB-inducing kinase. The E478G
mutant could not inhibit NF-kB activation in either case. We
also analysed the effect of OPTN on NF-kB activation induced by
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linearly di-ubiquitinated NEMO (Fig. 1c)31. OPTN-WT, but
not the E478G mutant, suppressed NF-kB activated by
di-ubiquitinated NEMO. This correlates with the ability of
OPTN to bind NEMO, as OPTN-WT could bind linearly
di-ubiquitinated NEMO, whereas the E478G mutant had
drastically reduced binding ability (Fig. 1d). These results
suggested that OPTN suppresses the canonical IKK activation
process and linear ubiquitin chain binding by OPTN-UBAN is
necessary for this effect.
In contrast to IKKa and IKKb, which do not bind to OPTN,
TBK1 and IKKe bound not only OPTN-WT but also OPTN

























































































































































































































































































































Figure 1 | ALS-associated OPTN mutants fail to suppress NF-jB activity. (a) Domain structure of OPTN and disease-associated mutations.
CC, coiled-coil; LZ, leucine zipper; LIR, LC3-interacting region; NZF, Npl4-type zinc ﬁnger; UBAN, ubiquitin binding in A20-binding IkB (ABIN) and NEMO
proteins. Blue, ALS-associated mutations; pink, POAG-associated mutations. (b) Effects of WTand mutants of OPTN on LUBAC- and TNF-a-induced NF-kB
activation were examined by luciferase assays in HEK293Tcells. Expression of WTand mutants of FLAG-OPTNs is shown by immunoblotting. (c) Effects of
WTand E478G mutant of OPTN on linear diubiquitin-conjugated NEMO were examined as in b. (b,c) Induction folds of NF-kB activity by luciferase assay
are shown as mean±s.e.m. (n¼ 3). Statistical signiﬁcance was assessed using one-way analysis of variance. *Po0.001 and **Po0.01, NS, not signiﬁcant.
(d) WT-OPTN, but not the E478G mutant, binds to linear di-ubiquitinated NEMO. Immunoprecipitation and immunoblotting were performed as indicated.
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OPTN and TBK1 were constitutively associated during TNF-a
stimulation (Supplementary Fig. 2a–c). Moreover, the NF-kB and
IFN pathways activated by TBK1 were not suppressed by
OPTN-WT or E478G (Supplementary Fig. 2d,e), collectively
indicating that the UBAN domain is not involved in the
collaborative OPTN functions with TBK1/IKKe.
UBAN domain of OPTN selectively binds to linear ubiquitin.
We next examined the ubiquitin-binding features of OPTN by a
maltose-binding protein (MBP) pull-down analysis (Fig. 2a).
OPTN-WT efﬁciently bound linear (M1)- and K63-linked
tetraubiquitin, but not K48-linked tetraubiquitin. The E478G
mutation drastically reduced OPTN binding to linear ubiquitin,
suggesting that the E478 residue in the UBAN domain is critical
for linear ubiquitin binding. OPTN-Q398X did not bind to either
type of ubiquitin and NEMO-WT efﬁciently bound to linear
ubiquitin9,32. A surface plasmon resonance (SPR) analysis
revealed that the association and dissociation rates of OPTN-
WT and linear tetraubiquitin were 5.09 103M–1 s–1 and
5.19 10 3 s–1, respectively, and the resultant afﬁnity (KD) was
1.02 10 6M (Fig. 2b). However, OPTN-E478G did not bind to
linear ubiquitin in the SPR analysis.
To clarify the molecular mechanism of linear ubiquitin
recognition by OPTN, we crystallized the human OPTN
CC2-UBAN region (residues 416–510) in complex with linear
tetraubiquitin and determined the complex structure at 2.7 Å
(Fig. 2c). The asymmetric unit contained four OPTN CC2-UBAN
monomers, which form two parallel coiled-coil dimer structures,
and two tetraubiquitin molecules (Supplementary Fig. 3).
Although we used the OPTN CC2-UBAN region for crystal-
lization experiments, the electron density for the majority of the
CC2 region in all OPTN molecules was very weak and thus we
modelled only the UBAN motif with some extensions on both
sides (residues 445–505 for the longest chain). In the crystal, the
third and fourth ubiquitin moieties of tetraubiquitin bind to one
side of OPTN-UBAN in the same asymmetric unit, whereas the
ﬁrst and second ubiquitin moieties bind to the other side of
OPTN-UBAN in the adjacent cell (Supplementary Fig. 3b,c).
Thus, there are two OPTN–diubiquitin complexes, composed of
one OPTN dimer and two diubiquitins, in the asymmetric unit.
The UBAN domain structure of OPTNdiubiquitin super-
imposed well on that of NEMO-UBANlinear diubiquitin, with a
root-mean square deviation of 0.72Å for 62 Ca atoms (Fig. 2d).
OPTN-UBAN binds to diubiquitin in a similar manner to that
observed in the structure of the NEMO-UBANlinear diubiquitin
complex9 rather than that in the NEMO-UBANK63 diubiquitin
complex (Fig. 2d,e and Supplementary Figs 4 and 5)33. The distal
ubiquitin is recognized mainly by hydrophobic interactions, with
additional polar interactions (Supplementary Fig. 4a). In contrast,
the proximal ubiquitin is recognized mainly by hydrogen bonding
(Supplementary Fig. 4b). The Glu478 side chain in OPTN
hydrogen bonds with the Arg74 side chain, near the linkage of the
linear ubiquitin chain, in the distal ubiquitin (Supplementary
Figs 4c and 5a). Glu478 also hydrogen bonds with the side chains
of Arg479 and Arg482 in the other OPTN protomer, which in
turn respectively hydrogen bond with Gln2 and Glu16 in the
proximal ubiquitin (Supplementary Figs 4c and 5a). The Asp474
side chain in OPTN hydrogen bonds with the Arg72 side chain
and the main chain nitrogen atom of Leu73 in the distal ubiquitin
(Supplementary Fig. 4a). These close recognitions of the linear
ubiquitin linkage may explain why the E478G mutation
speciﬁcally abolished linear ubiquitin-binding. Interestingly, the
OPTN residues involved in linear ubiquitin recognition, such as
D474 and E478, correlate with those crucial for the suppression
of LUBAC- and TNF-a-induced NF-kB activation (Fig. 1b).
This suggested that speciﬁc recognition of linear ubiquitin
by these OPTN-UBAN domain residues is indispensable for
suppression of NF-kB activation.
OPTN suppresses NF-jB activation. To examine the function
of OPTN in cells, we constructed OPTN-KO cells with the
CRISPR/Cas9 system, by targeting exon 5 of the OPTN gene. We
obtained two lines of OPTN-KO cells for both HeLa and BJAB
cells, designated as OPTN / -H1 and -H2 for HeLa cells and
OPTN / -B1 and -B2 for BJAB cells (Supplementary Fig. 6a).
Genome editing of the OPTN gene was conﬁrmed by deletion of
the restriction enzyme site, nucleotide sequencing, reduced OPTN
messenger RNA levels and immunoblotting (Supplementary
Fig. 6b–e). The OPTN deletion did not affect the expression of
TNFR and other NF-kB-activating factors such as LUBAC,
NEMO and RIP1 (Supplementary Fig. 6e).
Deletion of OPTN in HeLa cells enhanced NF-kB reporter
activity on TNF-a and interleukin (IL)-1b stimulations (Fig. 3a).
Phosphorylation of NF-kB factors such as IkBa, p105 and
IKKa/b was also enhanced in OPTN-KO HeLa cells stimulated
with TNF-a, although mitogen-activated protein kinases were
not affected (Fig. 3b). We also performed RNA interference-
mediated-OPTN knockdown (KD) in HeLa cells and conﬁrmed
the increased NF-kB activation on TNF-a stimulation14, as
shown by IkBa, p105, IKKa/b and p65 phosphorylation
(Supplementary Fig. 7a). However, NF-kB activation was more
enhanced in OPTN-KO HeLa cells, as compared with OPTN-KD
cells (compare Fig. 3b and Supplementary Fig. 7a). Intranuclear
translocation of p65 (Fig. 3c), and induction of NF-kB target
genes were also elevated in OPTN-KO cells (Fig. 3d,e). Similarly,
increases in NF-kB activation and target gene expression were
conﬁrmed in IL-1b-treated OPTN-KD and OPTN-KO HeLa cells
(Supplementary Figs 7b and 8). The knock-in of OPTN-WT,
but not the E478G mutant, to OPTN-KO cells recovered
the inhibitory effect on TNF-a-mediated NF-kB activation
(Supplementary Fig. 9). Furthermore, NF-kB target gene
expression was also enhanced in CD40L-stimulated OPTN-KO
BJAB cells (Fig. 3f). These results indicated that OPTN
physiologically functions as a negative regulator of the
canonical NF-kB activation pathway. Thus, the loss of
OPTN or the ALS-associated E478G mutation enhanced NF-kB
activation.
OPTN regulates TNFR signalling complex I. On TNF-a
stimulation, multiple proteins, such as RIP1, TNFR-associated
protein with a death domain (TRADD) and LUBAC, are
recruited to form the TNFR signalling complex I, which is crucial
for canonical IKK-mediated NF-kB activation34. To examine the
effect of OPTN on the formation of TNFR signalling complex I,
we stimulated OPTN-KO HeLa cells and their parental HeLa cells
with FLAG-TNF-a (Fig. 4a). NF-kB activation was elevated in
OPTN-KO cells stimulated with FLAG-TNF-a, as shown by the
enhanced phosphorylation of NF-kB factors, such as p65 and
p105 (Fig. 4a). Immunoprecipitation by FLAG–TNF-a showed
transient association of TNFR with RIP1, CYLD, TRADD,
NEMO and LUBAC. Compared with parental cells, association
and polyubiquitination of RIP1, HOIL-1L and SHARPIN were
enhanced in OPTN-KO HeLa cells, indicating that OPTN
regulates the association and retention of various molecules to
the TNFR complex. In contrast, the overexpression of OPTN
suppressed the associations of ubiquitinated RIP1, NEMO and
HOIP with TNFR (Supplementary Fig. 10). Collectively,
these results indicated that OPTN is a critical regulator of
TNFR complex I.
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Figure 2 | OPTN-UBAN domain is critical for linear ubiquitin binding. (a) The E478G mutation abrogated linear ubiquitin binding. In vitro MBP pull-down
experiments using linear (M1)-, K48- or K63-linked tetraubiquitins and MBP-fused lacZ, OPTN-WT, E478G, Q398X and NEMO-WTwere performed, and
the bound ubiquitin chain was detected by immunoblotting. (b) Kinetic analyses of OPTN and linear ubiquitin. Linear tetraubiquitin was immobilized and
various concentrations of OPTN-WT or E478G were tested. Grey lines, a global ﬁt to a 1:1 interaction model. (c) Crystal structure of OPTN-UBAN in
complex with linear diubiquitin (crystallized in the presence of linear tetraubiquitin). Each subunit of OPTN is coloured green and pink, respectively.
The distal and proximal ubiquitin moieties are coloured purple and cyan, respectively. Phosphorylation sites, such as Ser65 in ubiquitin and Ser473 in
OPTN, are coloured orange. (d) Superimposition of the structures of OPTNlinear diubiquitin and NEMOlinear diubiquitin (grey) (PDB 2ZVN).
(e) Superimposition of the structures of OPTNlinear diubiquitin and NEMOK63 diubiquitin (grey) (PDB 3JSV).
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We next searched for proteins that transiently bind to
OPTN during TNF-a-induced NF-kB activation. Interestingly,
immunoprecipitates of endogenous OPTN from HEK293T cells
were highly reactive to the anti-linear ubiquitin antibody on
TNF-a stimulation (Fig. 4b). This strongly suggested that OPTN
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Figure 3 | Enhanced NF-jB activation in OPTN-KO cells. (a) TNF-a- and IL-1b-induced NF-kB luciferase activities in OPTN-KO HeLa cells and their
parental cells. (b) Enhanced NF-kB activation in TNF-a-treated OPTN-KO HeLa cells. Cells were treated with TNF-a for the indicated times and
immunoblotting was performed using the indicated antibodies. (c) Accelerated TNF-a-induced nuclear translocation of p65 in OPTN-KO HeLa cells.
(d) Quantitative PCR (qPCR) analyses of NF-kB targets in TNF-a-treated parental and OPTN-KO HeLa cells. Relative expression of target mRNAs was
analysed using GAPDH as an internal standard. (e) Quantiﬁcation of secreted IL-6 from TNF-a-treated parental and OPTN-KO HeLa cells. (f) qPCR
analyses of NF-kB targets in CD40L-treated parental and OPTN-KO BJAB cells. (a,d,e,f) Mean±s.e.m. (n¼ 3). Statistical signiﬁcance was assessed using
one-way analysis of variance. *Po0.001, **Po0.01 and ***Po0.05.
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stimulation. Ubiquitinated RIP1 bound OPTN14 and we
conﬁrmed that TNF-a-stimulation indeed enhanced the
association of OPTN and RIP1 at both overexpressed and
endogenous levels (Fig. 4c,d).
As OPTN shares high homology with NEMO, we investigated
whether OPTN could also be linearly ubiquitinated similar
to NEMO, and thus have a dominant negative effect. In
overexpression experiments with HEK293T cells, OPTN bound
to LUBAC components (HOIP and HOIL-1L) and underwent
linear ubiquitination (Supplementary Fig. 11a,b). However,
we could not detect endogenous linear ubiquitination of OPTN
on TNF-a stimulation (Supplementary Fig. 11c). Moreover,
conjugation of di- and tetraubiquitins at the carboxy terminus of
OPTN, to mimic linearly ubiquitinated OPTN, did not induce
NF-kB activation, in contrast to NEMO (Supplementary
Fig. 11d)31. Overall, our results suggested that although OPTN
binds to LUBAC and can be linearly ubiquitinated at
overexpressed levels, it is neither a physiological substrate of
LUBAC at endogenous levels nor a potential activator of the
NF-kB pathway. More importantly, OPTN associates with
linearly ubiquitinated proteins, such as RIP1 and NEMO,
through its UBAN domain on TNF-a-stimulation, which is
important to regulate TNFR complex I.
OPTN regulates apoptosis. When TNFR signalling complex I
fails to activate NF-kB, this leads to the formation of a second
























































































































































Figure 4 | OPTN regulates TNFR signalling complex I. (a) Parental and OPTN-KO HeLa cells were stimulated with FLAG-TNF-a for the indicated
times and then TNFR complex I was immunoprecipitated using an anti-FLAG antibody, followed by immunoblotting using the indicated antibodies.
(b) Association of endogenous OPTN with free and/or conjugated linear ubiquitin chain on TNF-a stimulation. HEK293T cells were treated with
FLAG-TNF-a and anti-OPTN immunoprecipitates were blotted with an anti-linear ubiquitin antibody. (c,d) Association of OPTN with RIP1 on TNF-a
stimulation, examined at overexpressed (c) and endogenous (d) levels.
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complex, named complex II. Complex II induces apoptosis and
comprises RIP1, Fas-associated death domain protein (FADD)
and pro-caspase 8 (refs 35,36). As OPTN affected the complex I
components on TNF-a stimulation, we next investigated the
effect of OPTN on the subsequent TNF-a-induced complex II
formation. Combined TNF-a and cycloheximide (CHX)
treatments, but not the single treatment with either reagent,
induced accelerated cell death in OPTN-KO HeLa cells
(Fig. 5a–c). In contrast, cell death induced by doxorubicin
treatment, which activates the intrinsic mitochondrial apoptosis
pathway, was similar in either the presence or absence of OPTN
(Supplementary Fig. 12a). Enhanced cleavages of caspase 8,
caspase 3, PARP, RIP1 and CYLD were detected in OPTN-KO
HeLa cells (Fig. 5d). Similarly, enhanced cleavages of caspases 8
and 3 were detected in OPTN-KD cells (Supplementary Fig. 12b).
Such activation of caspases was inhibited by zVAD-FMK,
a pan-caspase inhibitor (Supplementary Fig. 12c). Interestingly,
knock-in of OPTN-WT to OPTN-KO HeLa cells restored
TNF-a-induced caspase activation to levels similar to that of
parental HeLa cells, but that of the E478G mutant showed only a
partial effect (Supplementary Fig. 12d). These results indicated
that OPTN suppresses TNF-a-induced apoptosis.
Although rapid cellular FLICE-like inhibitory protein (cFLIP)
turnover was detected at similar levels in both parental and
OPTN-KO HeLa cells after TNF-aþCHX treatment, the
immunoprecipitated caspase 8 revealed the drastically elevated
association of RIP1 and FADD to caspase 8 in OPTN-KO cells,
suggesting that the OPTN deletion enhanced complex II
formation independently of cFLIP (Fig. 5e). Furthermore, we
found that endogenous pro-caspase 8 constitutively associates
with OPTN in parental HeLa cells. To identify the inter-
action domains between caspase 8 and OPTN, we performed
co-immunoprecipitation analyses. When overexpressed in
HEK293T cells, the full-length active-site mutant of pro-caspase
8 co-immunoprecipitated with full-length OPTN. However, the
deletion of the N-terminal death effector domains (DEDs) in
caspase 8 abrogated its binding to OPTN (Fig. 5f). In addition,
the N-terminal portion of OPTN (residues 121–230), including
the leucine zipper and LIR domains, was crucial for caspase
8-binding (Fig. 5g). These results suggested that OPTN
physiologically binds to caspase 8 and regulates TNF-a-induced
apoptosis, and that the loss of OPTN accelerates complex II
formation.
Linear ubiquitin is involved in OPTN-associated ALS. Finally,
we investigated whether linear ubiquitin chains were involved
in the pathology of OPTN-associated ALS. In ALS patients,
ubiquitin- and TDP-43-positive inclusion bodies are reportedly
detected in motor neurons of the primary motor cortex,
brainstem and spinal cord24,37,38. We examined specimens from
an OPTN-associated ALS patient with the heterozygous E478G
missense mutation and another patient with the homozygous
Q398X nonsense mutation of OPTN24. Immunohistochemical
analyses of the lumbar anterior horn cells revealed
intracytoplasmic inclusions staining positive for linear ubiquitin
in comparison with control specimens (Fig. 6a–c). To verify
whether NF-kB activation was enhanced in OPTN-associated
ALS, we stained for phosphorylated p65 (P-p65) and
unexpectedly found that P-p65 was also localized in the
linear ubiquitin-positive intracytoplasmic inclusions (Fig. 6d–f).
We detected partial co-localization of linear ubiquitin and
P-p65 with phosphorylated TDP-43 (P-TDP-43) by double
immunoﬂuorescent staining analyses (Supplementary Fig. 13).
Our preliminary semi-quantitative analyses indicated that the
signals from 40% of linear ubiquitin and P-TDP-43 (two
cells/5P-TDP-43-positive cells), and 50% of P-p65 and P-TDP-43
(four cells/8P-TDP-43-positive cells) were merged. Furthermore,
we performed immunostaining with anti-cleaved caspase 3 and
anti-cleaved caspase 8 antibodies (Fig. 7), and detected diffuse
staining of these activated caspases in the cytoplasms of the spinal
anterior horn cells in the OPTN-associated ALS patient samples.
Neither activated caspase 3- nor caspase 8-positive cells were
found in the control subjects. On the other hand, the percentages
of cleaved caspase 3-positive cells among the residual anterior
horn cells in ALS patients with the E478G mutation and with the
Q398X mutation of OPTN were 14.5% (9/62 cells) and 15.9%
(7/44 cells), respectively, and those for cleaved caspase 8 were
14.3% (7/49 cells) and 16.7% (7/42 cells), respectively. We could
not detect the co-localization of cleaved caspase 3 or cleaved
caspase 8 and P-TDP-43, because of the diffuse caspase 3 and
caspase 8 staining patterns. Taken together, OPTN deﬁciency
causes the initial enhancement of NF-kB activation but is
followed by the impaired intranuclear translocation of NF-kB,
eventually leading to an apoptotic milieu induced by increased
complex II formation.
Discussion
In this study, we performed a comprehensive analysis using
known OPTN mutants associated with ALS and POAG. Most of
the ALS-associated OPTN mutants, but not the POAG-associated
mutants, lost the inhibitory effects on TNF-a- and LUBAC-
mediated canonical NF-kB activation (Fig. 1). This suggested that
impaired NF-kB regulation due to OPTN mutations is correlated
with ALS pathogenesis. In OPTN-associated POAG, OPTN
mutants such as E50K and M98K induce defects in vesicle
trafﬁcking and autophagy, and increase retinal ganglion cell death
by apoptosis29. In contrast, in OPTN-associated ALS, such as the
E478G mutation of OPTN, perturbations in NF-kB signalling,
IRF3 activation, autophagy, mitophagy and intracellular
trafﬁcking have been reported12,29. A recent study using
OPTN-KO mice indicated that the deﬁciency of OPTN affects
IFN signalling and Salmonella-induced autophagy, but not
NF-kB signalling39. However, unlike humans, OPTN-KO mice
did not exhibit any symptoms resembling glaucoma and ALS.
Therefore, it should be noted that differences in species and/or
OPTN-related signal transduction pathways might induce
neurodegenerative disorders speciﬁcally in humans. Our results
indicated that linear ubiquitin binding by OPTN-UBAN regulates
IKK-mediated NF-kB regulation, but not TBK1/IKKe-mediated
pathways (Fig. 3 and Supplementary Figs 1,2 and 6–9).
In MBP pull-down assays, linear ubiquitin binding was greatly
diminished by the E478G mutation, as compared with that of
OPTN-WT (Fig. 2a), and the KD value of full-length OPTN-WT
to linear ubiquitin was determined to be 1.0 mM (Fig. 2b), which
was close to that of NEMO-UBAN binding to linear ubiquitin9,32.
Crystal structure analyses revealed that the OPTN-UBAN
domain selectively binds to the linear ubiquitin chain in a
similar manner to the NEMO-UBAN domain9, and that the
ALS-associated E478 residue is essential for speciﬁc linear
ubiquitin recognition, but not K63-linked ubiquitin, as no
important interaction seems to occur between E478 and K63-
linked ubiquitin, as deduced from the structure of NEMO-UBAN
K63 diubiquitin (Fig. 2c–e and Supplementary Fig. 5). Our results
strongly suggested that ALS-associated mutations of OPTN-
UBAN cause defects in linear ubiquitin-binding ability and,
consequently, critically affect the pathogenesis of ALS by causing
dysregulation of IKK-mediated NF-kB activation.
In addition to linear ubiquitin-binding, we previously showed
that NEMO itself is linearly ubiquitinated at residues K285 and
K309 by LUBAC on NF-kB activation6. As the structures of
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Figure 5 | OPTN suppresses TNF-a-induced apoptosis. (a) Accelerated cell death in TNF-a- and CHX-treated OPTN-KO HeLa cells. Cell survival assays
were performed in the presence of TNF-a and/or CHX. Relative cell viabilities of WT (open circles) and OPTN-KO (ﬁlled circles) HeLa cells in the presence
of TNF-a and/or CHX are indicated. Mean±s.e.m. (n¼ 3). (b) Trypan blue exclusion assay. (c) ELISA for cytoplasmic histone-associated DNA fragments.
(b,c) Mean±s.e.m. (n¼ 3). Statistical signiﬁcance was assessed using one-way analysis of variance. *Po0.001, **Po0.01 and ***Po0.05. (d) Enhanced
cleavage of caspase 8, caspase 3 and PARP in TNF-a- and CHX-treated OPTN-KO HeLa cells. Immunoblotting of cell lysates, treated with TNF-a and CHX,
was performed using the indicated antibodies. (e) Enhanced TNFR complex II formation in TNF-a- and CHX-treated OPTN-KO cells. Cells were treated
with TNF-a and CHX for the indicated times, and cell lysates and anti-caspase 8 immunoprecipitates were immunoblotted by the indicated antibodies.
(f,g) Identiﬁcation of interacting regions between caspase 8 and OPTN. Co-immunoprecipitation experiments were performed using various mutants of
caspase 8 (d) and OPTN (e). Arrows, nonspeciﬁc signal.
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OPTN-UBAN and NEMO-UBAN are quite similar (Fig. 2d),
we tested whether OPTN could also be linearly ubiquitinated by
binding to LUBAC on overexpression (Supplementary Fig. 11).
OPTN was linearly ubiquitinated on overexpression, but not at
endogenous levels, suggesting that unlike NEMO, OPTN is not a
preferential substrate of LUBAC. This may be explained by
differences in the LUBAC afﬁnity between NEMO and OPTN.
LUBAC recognizes the CC2 region of NEMO, including amino
acid residues from Gln259 to Asp275, via the Npl4-type zinc
ﬁnger-1 domain of HOIP10. Differences in the coiled-coil
conformation and/or local amino acid residues between NEMO
and OPTN may affect the LUBAC afﬁnity. Thus, we concluded
that OPTN functions as a linear ubiquitin-binding protein
through its UBAN domain, and that linearly ubiquitinated
proteins, such as RIP1 and NEMO, are important candidates of
OPTN-binding. Indeed, in CRISPR/Cas9-mediated OPTN-KO
HeLa cells, immunoprecipitation of TNF-a revealed prolonged
association and polyubiquitination of TNFR complex I
components, such as RIP1, NEMO and LUBAC (Fig. 4a),
whereas the overexpression of OPTN showed the opposite
reaction (Supplementary Fig. 10). Thus, these results suggested
that OPTN affects the ubiquitination and association of TNFR
complex I components such as RIP1 and NEMO by competing
through its linear ubiquitin-binding UBAN domain.
In the absence of OPTN, complex II formation was accelerated
during the extrinsic apoptosis pathway induced by TNF-a
and CHX treatments (Fig. 5a–e). OPTN also physiologically
associated with caspase 8 at the DED domains (Fig. 5e,f),
which are important regions for the recruitment of other
DED domain-containing proteins, such as FADD40. As the
deubiquitination of RIP1 by CYLD, a major deubiquitinase in the
NF-kB pathway that functions by hydrolysing K63 and linear
ubiquitin chains41, is a key step to induce complex II formation42







Figure 6 | Intracytoplasmic inclusions of OPTN-associated ALS are immunoreactive to linear ubiquitin. Immunohistochemical staining of specimens
from a leukaemia patient (control) and ALS patients with the heterozygous OPTN-E478G mutation and the homozygous OPTN-Q398X mutation was








Figure 7 | Cleaved caspase 3 and cleaved caspase 8 immunoreactivities are increased in the cytoplasms of spinal anterior horn cells from
OPTN-associated ALS cases. Immunohistochemical staining of specimens from a control subject and ALS patients with the heterozygous OPTN-E478G
mutation and with the homozygous OPTN-Q398X mutation were performed using anti-cleaved caspase 3 (a–c) and anti-cleaved caspase 8 (d–f).
Faintly increased diffuse cytoplasmic immunoreactivities of the spinal anterior horn cells from the OPTN-associated ALS patients are indicated by arrows
(b,c,e,f). Scale bar, 20mm.
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deubiquitination activity, due to the absence of OPTN, may result
in enhanced complex II formation.
ALS is a fatal neurodegenerative disorder affecting large motor
neurons of the brain and spinal cord. Protein/RNA aggregate
formation, failures in clearance by proteasomes and autophagy,
and neuroinﬂammation by the NF-kB and IFN signalling
pathways play crucial roles in the molecular pathogenesis of
ALS25. OPTN-associated ALS is rare (o1%) in familial and
sporadic ALS25, but the patients have intracytoplasmic inclusions
in the anterior horn cells and immunoreactivity for ubiquitin and
TDP-43 (refs 24,38). We found that these intracytoplasmic
inclusions, in the spinal cord of ALS patients with the
heterozygous OPTN-E478G or homozygous Q398X mutation,
stained positive for linear ubiquitin and activated NF-kB (P-p65)
in partial co-localization with P-TDP-43 (Fig. 6 and
Supplementary Fig. 13). A recent report demonstrated that the
co-localization of TDP-43 and p65 disturbs the nuclear
translocation of p65, thus also supporting the involvement of
NF-kB dysregulation in ALS44. Moreover, cleaved caspase 3 was
also detected in the OPTN-associated ALS patients, suggesting
enhanced apoptosis in the absence of OPTN. We previously
reported that the Optn-KD in Neuro2a cells increases apoptosis45.
Although restoration of the WT and POAG-associated E50K
OPTN mutant suppressed cell death, ALS-associated OPTN
mutants such as Q398X and E478G could not, suggesting that
apoptosis is also pivotal in ALS pathogenesis.
OPTN has recently attracted much attention as a receptor/
regulator of autophagy. First, OPTN reportedly regulates
autophagic clearance of ubiquitin-coated cytosolic Salmonella in
infected HeLa cells, through phosphorylation of OPTN-LIR by
TBK1 (ref. 17). OPTN also recognizes protein aggregates during
autophagy46. As for mitophagy, OPTN and NDP52 have been
linked to PINK1 (PTEN-induced putative kinase 1)- and parkin-
mediated mitophagy, and OPTN-UBAN is required for this
process18,19,20. Phosphorylations of Ser65 in both ubiquitin and
parkin are critical triggers for mitophagy and are involved in the
pathophysiology of Parkinson’s disease47; however, the effect of
ubiquitin phosphorylation on the interaction between ubiquitin
and OPTN remains controversial. One report found that OPTN
exhibits higher afﬁnity to the phosphomimetic S65D ubiquitin
than to WT ubiquitin19, whereas others reported that OPTN
shows lower afﬁnity to phosphorylated K63- and M1-linked
ubiquitins, as compared with unphosphorylated ubiquitin20,48.
Our structural analysis revealed that Ser65, in both the distal and
proximal ubiquitins in the linear ubiquitin chain, does not
directly interact with OPTN-UBAN (Fig. 2c and Supplementary
Fig. 14). Recently, TBK1 was found to phosphorylate Ser473 and
Ser513 of OPTN, in addition to the previously identiﬁed Ser177,
and the phosphorylation of Ser473 plays a major role to promote
ubiquitin binding20. Our structural analysis suggested that Ser473
of OPTN hydrogen bonds with Arg74 of the distal ubiquitin and
thus the phosphorylation of this residue might affect the ubiquitin
binding of OPTN (Fig. 2c and Supplementary Fig. 14).
Defects in autophagy and mitophagy result in the
accumulation of misfolded proteins and damaged organelles, in
a hypothetical model of ALS pathogenesis49. Interestingly,
our results showed that intracytoplasmic inclusions in
OPTN-associated ALS patients stained positive for linear
ubiquitin chain (Fig. 6), suggesting that linear ubiquitination is
involved in the molecular pathogenesis of ALS. We conﬁrmed the
role of OPTN as a regulator of NF-kB activation and apoptosis,
especially in the context of OPTN-associated ALS. Taken
together, we speculate that OPTN, with its linear ubiquitin-
binding ability, stands at the cross-roads of NF-kB activation,
apoptosis and possibly autophagy, resulting in the complex and
multifactorial pathogenesis of ALS.
Methods
Plasmids. The open reading frames of human OPTN, caspase 8 and the other
complementary DNAs6,8 were ampliﬁed by reverse transcription–PCR. Mutants of
these cDNAs were prepared by the QuikChange method and the whole nucleotide
sequences were veriﬁed. The cDNAs were ligated to the appropriate epitope
sequences and cloned into the pcDNA3.1 (Invitrogen) and pMAL-c2x
(New England Biolabs) vectors.
Antibodies. The following antibodies were used for immunoblotting and full-size
images for immunoblottings are presented in Supplementary Fig. 15. Catalogue
number and dilutions are indicated in the parentheses. P-IkBa (9246; 1:1,000),
IkBa (4812; 1:1,000), P-p105 (4806; 1:1,000), p105 (13586; 1:1,000), P-p65 (3033;
1:1,000), p65 (8242; 1:1,000), P-IKKa/b (2697; 1:1,000), P-JNK (4668; 1:1,000),
JNK (5668; 1:1,000), P-ERK (4370; 1:2,000), ERK (4695; 1:2,000), caspase 8 (4790;
1:1,000), cleaved caspase 8 (Asp391) (9496; 1:1,000), caspase 3 (9662; 1:1,000),
cleaved caspase 3 (9661; 1:1,000), PARP (9542; 1:1,000), CYLD (8462; 1:1,000),
TBK1 (3504; 1:1,000) and Lamin A/C (4777; 1:2,000) were obtained from Cell
Signaling. OPTN (clone C-2, sc-166576; 1:1,000), ubiquitin (clone P4D1, sc-8017;
1:1,000), TNFR1 (clone H271, sc-7895; 1:1,000), IKKa/b (clone H-470, sc-7607;
1:1,000), TRADD (sc-46653; 1:1,000) and NEMO (clone FL-419, sc-8330; 1:1,000)
were purchased from Santa Cruz Biotechnology. RIP1 (610458; 1:1,000) and FADD
(610399; 1:1,000) were from BD Transduction Laboratories. OPTN (A301-829A,
Bethyl and Proteintech; 1:1,000), linear ubiquitin (clone LUB9, MABS451,
Millipore; 1:1,000), tubulin (CLT9002, Cedarlane; 1:3,000), NEMO (clone EA2-6,
K0159-3, MBL; 1:1,000), HOIP (SAB2102031, Sigma-Aldrich; 1:1,000), HOIL-1L
(NBP1-88301, Novus Biologicals; 1:1,000) and SHARPIN (14626-1-AP,
Proteintech; 1:1,000) were also used.
Cell culture and luciferase assay. HEK293T and HeLa cells (ATCC) were
cultured in DMEM containing 10% fetal bovine serum, 100 IUml 1 penicillin G
and 100 mgml 1 streptomycin, and BJAB cells (ATCC) were maintained in RPMI
containing 10% fetal bovine serum and antibiotics, at 37 C under 5% CO2.
Transfection experiments were performed using Lipofectamine 2000 or TurboFect
(Thermo Fisher). For KD experiments, control siRNA (sc-37007) and OPTN
siRNA (sc-39054), obtained from Santa Cruz Biotechnology, were transfected by
Lipofectamine RNAiMAX (Thermo Fisher).
The pGL4-IFNb-promoter-Luc or pGL4-NF-kB-Luc plasmid was
co-transfected into HEK293T or HeLa cells with the pGL4-Renilla-Luc/TK
plasmid50. At 24 h after transfection, the cells were lysed and the luciferase
activity was measured in a GloMax 20/20 luminometer (Promega), using the
Dual-Luciferase Reporter Assay System (Promega).
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MBP pull-down assay. MBP-tagged full-length OPTN and its mutants (E478G,
Q398X), full-length NEMO and MBP-LacZ were expressed in Escherichia coli
Rosetta 2 (DE3) (Novagen) and puriﬁed using amylose resin (New England
Biolabs). To examine the ubiquitin-binding ability, MBP-fusion proteins (0.8 mM)
and tetraubiquitin (2 mM) were incubated in reaction buffer (50mM Tris-HCl
pH 7.5, 150mM NaCl, 1mM dithiothreitol, 0.1% NP-40 and 250 mgml 1 BSA) at
37 C for 1 h, followed by the addition of amylose resin51. The samples were further
incubated at 4 C for 1 h with gentle rotation and then the beads were washed three
times with the buffer without BSA and analysed by SDS–PAGE. The bound
ubiquitin was detected by immunoblotting using an anti-ubiquitin antibody and
MBP fusion proteins were stained with Coomassie Brilliant Blue.
SPR analysis. The kinetic analysis was conducted with a Biacore X100 apparatus
(GE Healthcare). A CM5 sensor chip and HBS-EPþ running buffer (10mM
Hepes-NaOH pH 7.4, 150mM NaCl, 0.05% Tween 20 and 3mM EDTA) were
used. The temperature of the ﬂow cells was kept at 25 C. Linear tetraubiquitin and
BSA were respectively immobilized on the measuring cell and the reference cell by
amine coupling. The immobilization level of linear tetraubiquitin was around
500 RU. In each cycle, a different concentration of OPTN protein diluted by
HBS-EPþ buffer was injected into the ﬂow cells, at 30 ml min 1 for 120 s. The
dissociation time was 300 s. Finally, the sensor chip was regenerated by injecting
10mM NaOH, for 30 s at 10ml min 1. Data analysis was conducted with the
BIAevaluation software.
Crystallography. The gene encoding human OPTN CC2 and UBAN domain
(residues 416–510) was cloned into the pGEX-6P vector (GE Healthcare). The
glutathione S-transferase-tagged OPTN CC2-UBAN protein was overexpressed in
E. coli Rosetta 2 (DE3) and puriﬁed with glutathione Sepharose 4B resin, followed
by on-column cleavage of glutathione S-transferase using Turbo3C (HRV3C)
protease (Accelagen). The eluted protein was further puriﬁed by Resource Q
column chromatography (GE Healthcare), followed by Superdex 75 column
chromatography (GE Healthcare). Linear tetra-ubiquitin was expressed in E. coli
and puriﬁed by heat treatment and ion exchange chromatography using a HiTrap
SP column (GE Healthcare), followed by Superdex 200 column chromatography
(GE Healthcare)51. The ﬁnal concentrations of the OPTN and tetraubiquitin stock
solutions were 3.8 and 6.2mgml 1, respectively. Crystals were obtained within
1 week at 20 C by the hanging drop vapour diffusion method, by mixing 1 ml
protein solution and 1 ml reservoir solution (16% PEG 3350 and 250mM HCOOK).
The crystals were cryoprotected in the reservoir solution supplemented with 25%
ethylene glycol and ﬂash cooled in liquid nitrogen. X-ray diffraction experiments
were performed at beamline BL41XU at SPring-8 (Hyogo, Japan), at 1 Å
wavelength and 100K.
The data set was processed with XDS52. The structure was determined by
sequential molecular replacement, using Phaser53 and MOLREP54. The ﬁrst
molecular replacement search was performed using Phaser53, with the linear
diubiquitin and a polyalanine model of the NEMO CC2-UBAN dimer taken from
the NEMO-linear diubiquitin complex structure (PDB: 2ZVN) as search models.
Two copies of diubiquitin and two copies of the CC2-UBAN dimer were
successfully placed. The solution was ﬁxed and the remaining two linear
diubiquitin molecules were placed using MOLREP54. Manual model building
and reﬁnement were performed using COOT55 and PHENIX56, respectively.
A representative electron density map is shown in Supplementary Fig. 4c. In the
Ramachandran plot, 95.5, 4.4 and 0.1% of the residues were in the favoured,
allowed and outlier regions, respectively. Data collection and reﬁnement statistics
are summarized in Table 1.
Construction of OPTN-KO cells. The gRNA_cloning vector (41824) and
pCAG-hCas9 (51142) were obtained from Addgene. The nucleotide sequence
50-CCcacgagaacagtctccactg-30 in exon 5 of the human OPTN gene was selected as
the target for gRNA. These plasmids and a puromycin-resistant vector (pXS-Puro)
were co-transfected into HeLa and BJAB cells. Two days after transfection, cells
were selected with puromycin for 2 days and then cell colonies were obtained by
limiting dilution. Genome editing of the OPTN gene was screened by PCR and
BssSI digestion assays, and nucleotide mutations were conﬁrmed by sequencing.
Quantitative PCR and ELISA. Cell lysis, reverse-transcription and quantitative
PCR were performed with SuperPrep Cell Lysis, RT Kit for quantitative PCR and
Power SYBR Green PCR Master Mix (Life Technologies), respectively, according to
the manufacturer’s instructions. Quantitative real-time PCR was performed with a
Step-One-Plus PCR system (Applied Biosystems) by the DDCT method, using the
following oligonucleotides: IL-6 sense, 50-AGCCACTCACCTCTTCAGAAC-30
and IL-6 anti-sense, 50-GCCTCTTTGCTGCTTTCACAC-30 ; BIRC3 sense,
50-AGATGAAAATGCAGAGTCATCAAT-30 and BIRC3 anti-sense, 50-CATGA
TTGCATCTTCTGAATGG-30 ; ICAM1 sense, 50-GTGGTAGCAGCCGCAGT-30
and ICAM1 anti-sense, 50-TTCGGTTTCATGGGGGT-30; NFKBIA sense,
50-CGGGCTGAAGAAGGAGCGGC-30 and NFKBIA anti-sense, 50-ACGA
GTCCCCGTCCTCGGTG-30 ; BCL-2a sense, 50-CAGGAGAATGGATAAGGC
AAA-30 and BCL-2a anti-sense, 50-CCAGCCAGATTTAGGTTCAAA-30 ;
TNFAIP3 sense, 50-CATGCATGCCACTTCTCAGT-30 , and TNFAIP3 anti-sense,
50-CATGGGTGTGTCTGTGGAG-30 ; and GAPDH sense, 50-AGCAACAGGGT
GGTGGAC-30 and GAPDH anti-sense, 50-GTGTGGTGGGGGACTGAG-30 .
Secreted human IL-6 was measured by using an ELISA kit (eBioscience).
TNFR1 complex I analysis. TNFR complex formation on TNF-a stimulation was
analysed using FLAG-tagged TNF-a51. Brieﬂy, HeLa cells were stimulated for the
indicated times with 1 mgml 1 FLAG-tagged TNF-a and then lysed in 1ml lysis
buffer (50mM Tris-HCl pH 7.5, 150mM NaCl, 1% Triton X-100 and complete
protease inhibitor cocktail) for 15min on ice. Lysates were immunoprecipitated
with 15ml anti-FLAG M2 beads (Sigma) overnight at 4 C. The beads were
recovered by centrifugation, washed eight times with 1ml of lysis buffer and then
analysed by SDS–PAGE and immunoblotting.
Cell survival assay. The number of viable cells was measured with a CellTiter
96 AQueous Non-Radioactive Cell Proliferation Assay kit (Promega), based on an
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium) compound-based colorimetric assay and by the trypan blue
exclusion assay. Moreover, cytoplasmic histone-associated DNA fragments
(mono- and oligonucleosomes) generated after induced cell death were measured
by a cell-death detection ELISA (Roche), according to the manufacturer’s
instructions. zVAD-FMK (BD Biosciences) was used as a pan-caspase inhibitor.
Patient information. The patient with the proband of homozygous recessive
OPTN-Q398X developed with the onset of dysarthria, muscle weakness and
increased deep tendon reﬂex at 52 years of age24,37. On the other hand, the patient
with the proband of heterozygous dominant OPTN-E478G showed muscle
weakness, dysarthria, increased deep tendon reﬂex and tongue atrophy at 56 years
of age24,38.
Immunohistochemistry. For neuropathological examinations, formalin-ﬁxed
parafﬁn-embedded 6 mm-thick sections were deparafﬁnized, autoclaved and
incubated overnight with a given primary antibody, such as anti-linear ubiquitin
(clone LUB9, MABS451, Millipore; 1:100), anti-phospho-p65 (pSer536) (600-401-
265, Rockland; 1:200), anti-cleaved caspase 3 (9661, Cell Signalling; 1:100) and
anti-cleaved caspase 8 (9496, Cell Signalling; 1:50). Bound antibodies were detected
by a Vectastain Elite ABC kit (Vector Laboratories), with 3,3’-diaminobenzidine
tetrahydrochloride as the chromogen38. For double immunoﬂuorescence staining,
rabbit polyclonal anti-phospho-TDP-43 antibody (pSer409) (TIP-PTD-P03,
Cosmo Bio; 1:2,000) and a mouse monoclonal anti-phospho-TDP-43 antibody
(pSer 409/410) (TIP-PTD-M01, Cosmo Bio; 1:2,000) were treated with anti-linear
ubiquitin and P-p65 antibodies, respectively. The primary antibodies were detected
with Alexa Fluor 488- (Donkey anti-mouse, A21202; Donkey anti-rabbit, A21200;
Molecular Probes; 1:200) or Alexa Fluor 546-conjugated secondary antibodies
(Donkey anti-mouse, A10036; Donkey anti-rabbit, A10040; 1:200) and observed
with an FLUOVIEW FV-1000 confocal laser scanning microscope (Olympus)38.
Procedures involving the use of human materials were performed in accordance
with ethical guidelines set by Wakayama Medical University and Declaration of
Helsinki. For quantitative study of these activated caspase-positive cells, we
obtained four to six distinct sections from each case for each antibody and two
examiners, who had no information regarding the clinical condition of the
individual providing the spinal specimen, made observations. Only anterior horn
cells with a distinct nucleus and nucleolus were counted.
Statistical analysis. One-way analysis of variance followed by a post-hoc Tukey’s
honest signiﬁcant difference test was performed, using the KaleidaGraph software.
For all tests, a P-value of o0.05 was considered statistically signiﬁcant.
Data availability. The coordinates and structure factors of OPTN CC2-UBAN
region in complex with linear tetraubiquitin have been deposited in the Protein
Data Bank under the accession codes 5B83. The authors declare that data sup-
porting the ﬁndings of this study are available within the article and its
Supplementary Information ﬁles or are available from the corresponding authors
on request.
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